A Phase 1, Single-site, Open-label Study to Determine the Safety and Tolerability of Single and Multiple Doses of Intranasally Administered LMN-301 in Healthy Volunteers
Latest Information Update: 12 Aug 2025
At a glance
- Drugs LMN 301 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Lumen Bioscience
Most Recent Events
- 25 Apr 2024 Status changed from recruiting to completed.
- 02 Oct 2023 Status changed from not yet recruiting to recruiting.
- 09 Jan 2023 New trial record